BJ Jones

Mr. Jones is the Chief Commercial Officer of NewAmsterdam Pharma. He was previously Chief Commercial Officer at Biohaven Pharmaceuticals from 2019 to 2022. Following its $11.6B acquisition by Pfizer, he oversaw the company's commercial integration. He has over 25 years of commercial experience in the healthcare industry and has held executive leadership roles of increasing responsibility at Takeda Pharmaceuticals, Astra Zeneca, Bristol-Myers Squibb, Boehringer-Ingelheim and NitroMed. He has significant experience in mass market product launches, including Excedrin Migraine, Abilify, Farxiga, Pradaxa, BiDil and most recently, Nurtec ODT. BJ has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, depression), CV (CHF, atrial fibrillation), diabetes (type 2 - oral and injectable), respiratory, GI, and infectious disease.

He holds a Bachelor of Science degree from the U.S. Air Force Academy, a Master of Science degree in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business.

Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major.